Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 656-657

  Himmelmann, Andreas ^a   Tchinda, Joëlle ^b  

^a Onco Haematological Center Zug   (Switzerland)

^b Children's Hospital Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; LENALIDOMIDE; STEROID; VALPROIC ACID;

5Q- SYNDROME; ADULT; AGED; ARTICLE; ASTHMA; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 5Q; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FACE EDEMA; FEMALE; HUMAN; MACROCYTIC ANEMIA; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; REMISSION; RETICULOCYTE COUNT; SEIZURE; SHORT COURSE THERAPY; THROMBOCYTOPENIA;

AGED; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84858752796     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.023     Document Type: Article

References (7)

1. Padron E., Komrokji R., List A.F. Biology and treatment of the 5q- syndrome. Expert Rev Hematol 2011, 4:61-69.
2. Giagounidis A.A., Haase S., Heinsch M., Göhring G., Schlegelberger B., Aul C. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q) MDS patients with unexpected responses. Ann Hematol 2007, 86:133-137.
3. Dürr D., Siciliano R.D., Hummel Y., O'Meara A., Hirschi A., Burkhard R., et al. Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?. Ann Hematol 2010, 89:105-106.
4. Xu F., Li X., Chang C., He Q., Zhang Z., Zhang Q., et al. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q). Leuk Res 2009, 33:e199-e202.
5. Cannella L., Latagliata R., Breccia M., Carmosino I., Loglisci G., Volpicelli P., et al. Very short term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol 2011, May.
6. Pellagatti A., Jädersten M., Forsblom A., Cattan H., Christensson B., Emanuelsson E., et al. Lenalidomide inhibits the malignant clone and upregulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104:11406-11411.
7. Heise C., Carter T., Schafer P., Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010, 10:1663-1672.